Picture of Nicox SA logo

ALCOX — Nicox SA News Story

0.000.00%
fr flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Brief: Nicox Q1 Net Revenue At EUR 0.8 Mln

April 19 (Reuters) - Nicox SA  NCOX.PA :
    * NICOX PROVIDES FIRST QUARTER 2023 FINANCIAL AND BUSINESS
HIGHLIGHTS
    * NET REVENUE OF EUR 0.8 MILLION FOR Q1 OF 2023
    * CASH POSITION OF EUR 21.4 MILLION AS OF MARCH 31
    * APPROVAL AND LAUNCH OF ZERVIATE IN CHINA BY OCUMENSION:
EXPECTED
IN 2024
    * DENALI PHASE 3 CLINICAL TRIAL EVALUATING NCX 470 IN
PATIENTS
WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION: TOPLINE RESULTS
EXPECTED IN 2025

Source text for Eikon:  ID:nGNX5c2tGV 
Further company coverage:  NCOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

Recent news on Nicox SA

See all news